ENGINEERING MEDICINES TO IMPROVE PATIENT CARE Investors News Releases Year None20232022202120202019201820172016 March 8, 2023 Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates March 7, 2023 Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society March 3, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 1, 2023 Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023 February 28, 2023 Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference February 7, 2023 Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference February 6, 2023 Viridian Appoints Scott Myers as President and Chief Executive Officer February 2, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) January 8, 2023 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) January 5, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 11
Year None20232022202120202019201820172016 March 8, 2023 Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates March 7, 2023 Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society March 3, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 1, 2023 Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023 February 28, 2023 Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference February 7, 2023 Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference February 6, 2023 Viridian Appoints Scott Myers as President and Chief Executive Officer February 2, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) January 8, 2023 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) January 5, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 11
March 8, 2023 Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
March 7, 2023 Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society
March 1, 2023 Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
February 7, 2023 Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
February 2, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 8, 2023 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
January 5, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)